# A Study to Investigate the Effects of Rifampicin on the Pharmacokinetics of Aleglitazar in Healthy Volunteers

> **NCT01679639** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** aleglitazar
- **DRUG:** rifampicin

## Key facts

- **NCT ID:** NCT01679639
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01679639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01679639, "A Study to Investigate the Effects of Rifampicin on the Pharmacokinetics of Aleglitazar in Healthy Volunteers". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT01679639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*